Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07679360 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer

StatusRecruiting
PhasePhase 3
Started2026-09-02
View on ClinicalTrials.gov ↗

Amendment history

2026-09-08
Study Status, Contacts/Locations v1
Recruitment opened
Start dateestimated 2026-07→confirmed 2026-09-02
Study sitesdetails revised at 1 of 1 site
2026-06-25
Original filing
It is a randomized, open label, positive drug controlled, multicenter design Phase III clinical trial, aims to compare the efficacy and safety of SHR-A1811 combined with Adebrelimab and the treatment selected by the researchers in the adjuvant treatment of triple negative breast cancer with invasive residual cancer after neoadjuvant treatment, and to explore the PK characteristics and immunogenicity of SHR-A1811 and Adebrelimab.
Trial Details
NCT Number NCT07679360
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Triple Negative Breast Cancer
Enrollment 1,000 participants
Start Date 2026-09-02
Primary Completion 2030-12 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2026-09-09